nasdaq:mcrb
|
5148589
|
Mar 23rd, 2024 12:00AM
|
Seres Therapeutics
|
22K
|
329.00
|
Open
|
|
Mar 22nd, 2024 11:54PM
|
Mar 23rd, 2024 07:03PM
|
Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis.
For more information, please visit http://www.serestherapeutics.com/ .
|
Open
|
Biotechnology, Therapeutics, and Microbiome
|
Open
|
200 Sidney Street
|
Cambridge
|
Massachusetts
|
US
|
02139
|
|
Seres Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:mcrb
|
5148589
|
Mar 22nd, 2024 12:00AM
|
Seres Therapeutics
|
22K
|
329.00
|
Open
|
|
Mar 21st, 2024 11:44PM
|
Mar 22nd, 2024 06:51PM
|
Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis.
For more information, please visit http://www.serestherapeutics.com/ .
|
Open
|
Biotechnology, Therapeutics, and Microbiome
|
Open
|
200 Sidney Street
|
Cambridge
|
Massachusetts
|
US
|
02139
|
|
Seres Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:mcrb
|
5148589
|
Mar 21st, 2024 12:00AM
|
Seres Therapeutics
|
22K
|
331.00
|
Open
|
|
Mar 20th, 2024 11:57PM
|
Mar 21st, 2024 05:35PM
|
Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis.
For more information, please visit http://www.serestherapeutics.com/ .
|
Open
|
Biotechnology, Therapeutics, and Microbiome
|
Open
|
200 Sidney Street
|
Cambridge
|
Massachusetts
|
US
|
02139
|
|
Seres Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:mcrb
|
5148589
|
Mar 20th, 2024 12:00AM
|
Seres Therapeutics
|
22K
|
331.00
|
Open
|
|
Mar 20th, 2024 12:38AM
|
Mar 20th, 2024 07:36PM
|
Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis.
For more information, please visit http://www.serestherapeutics.com/ .
|
Open
|
Biotechnology, Therapeutics, and Microbiome
|
Open
|
200 Sidney Street
|
Cambridge
|
Massachusetts
|
US
|
02139
|
|
Seres Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:mcrb
|
5148589
|
Mar 19th, 2024 12:00AM
|
Seres Therapeutics
|
22K
|
331.00
|
Open
|
|
Mar 18th, 2024 11:32PM
|
Mar 19th, 2024 06:08PM
|
Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis.
For more information, please visit http://www.serestherapeutics.com/ .
|
Open
|
Biotechnology, Therapeutics, and Microbiome
|
Open
|
200 Sidney Street
|
Cambridge
|
Massachusetts
|
US
|
02139
|
|
Seres Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:mcrb
|
5148589
|
Mar 18th, 2024 12:00AM
|
Seres Therapeutics
|
22K
|
331.00
|
Open
|
|
Mar 17th, 2024 11:54PM
|
Mar 18th, 2024 07:20PM
|
Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis.
For more information, please visit http://www.serestherapeutics.com/ .
|
Open
|
Biotechnology, Therapeutics, and Microbiome
|
Open
|
200 Sidney Street
|
Cambridge
|
Massachusetts
|
US
|
02139
|
|
Seres Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:mcrb
|
5148589
|
Mar 16th, 2024 12:00AM
|
Seres Therapeutics
|
22K
|
333.00
|
Open
|
|
Mar 15th, 2024 11:24PM
|
Mar 16th, 2024 07:08PM
|
Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis.
For more information, please visit http://www.serestherapeutics.com/ .
|
Open
|
Biotechnology, Therapeutics, and Microbiome
|
Open
|
200 Sidney Street
|
Cambridge
|
Massachusetts
|
US
|
02139
|
|
Seres Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:mcrb
|
5148589
|
Mar 15th, 2024 12:00AM
|
Seres Therapeutics
|
22K
|
335.00
|
Open
|
|
Mar 15th, 2024 12:58AM
|
Mar 15th, 2024 08:57AM
|
Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis.
For more information, please visit http://www.serestherapeutics.com/ .
|
Open
|
Biotechnology, Therapeutics, and Microbiome
|
Open
|
200 Sidney Street
|
Cambridge
|
Massachusetts
|
US
|
02139
|
|
Seres Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:mcrb
|
5148589
|
Mar 14th, 2024 12:00AM
|
Seres Therapeutics
|
22K
|
335.00
|
Open
|
|
Mar 13th, 2024 11:22PM
|
Mar 14th, 2024 12:19PM
|
Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis.
For more information, please visit http://www.serestherapeutics.com/ .
|
Open
|
Biotechnology, Therapeutics, and Microbiome
|
Open
|
200 Sidney Street
|
Cambridge
|
Massachusetts
|
US
|
02139
|
|
Seres Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:mcrb
|
5148589
|
Mar 13th, 2024 12:00AM
|
Seres Therapeutics
|
22K
|
340.00
|
Open
|
|
Mar 12th, 2024 11:17PM
|
Mar 13th, 2024 10:49AM
|
Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis.
For more information, please visit http://www.serestherapeutics.com/ .
|
Open
|
Biotechnology, Therapeutics, and Microbiome
|
Open
|
200 Sidney Street
|
Cambridge
|
Massachusetts
|
US
|
02139
|
|
Seres Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|